Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 19/20 | 0.61 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL4498118 | 0.92 | SLC6A2 (0.67) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4492291 | 0.91 | SLC6A2 (0.66) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4559200 | 0.91 | SLC6A4 (0.63) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL5994777 | 0.89 | SLC6A4 (0.66) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4326897 | 0.88 | SLC6A2 (0.55) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4324688 | 0.88 | SLC6A2 (0.55) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4321600 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4486146 | 0.86 | SLC6A4 (0.64) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4322246 | 0.85 | SLC6A2 (0.53) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4324483 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A2 1/4885SLC6A3 2/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.